| Michael Weisner, | |
|
900 Plaza Dr, Montoursville, PA 17754-2448 | |
| (570) 368-3037 | |
| Not Available |
| Full Name | Michael Weisner |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 42 Years |
| Location | 900 Plaza Dr, Montoursville, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1114966850 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD029362E (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Susquehanna Home Care And Hospice Services | Williamsport, PA | Home health agency |
| Williamsport Regional Medical Center | Williamsport, PA | Hospital |
| Upmc Susquehanna Muncy | Muncy, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Susquehanna Physician Services | 2264336460 | 492 |
News Archive
Exposure to environments outside a comfortable temperature could help tackle major metabolic diseases, such as diabetes and obesity, and should be reflected in modern building practices, finds a study published today.
Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has executed an agreement with The Research Foundation of the State University of New York (SUNY), acting for and on behalf of Binghamton University (Binghamton, NY).
Alkermes plc today announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441 mg, p<0.001 aripiprazole lauroxil 882 mg), which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014.
Whether you love it, hate it or are just plain confused, the ACA is the law of the land. The thousand-page law covers a lot of ground and figuring out what part of it has to do with you can be a challenge.
› Verified 8 days ago
| Entity Name | Susquehanna Physician Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1023065885 PECOS PAC ID: 2264336460 Enrollment ID: O20040415000779 |
News Archive
Exposure to environments outside a comfortable temperature could help tackle major metabolic diseases, such as diabetes and obesity, and should be reflected in modern building practices, finds a study published today.
Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has executed an agreement with The Research Foundation of the State University of New York (SUNY), acting for and on behalf of Binghamton University (Binghamton, NY).
Alkermes plc today announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441 mg, p<0.001 aripiprazole lauroxil 882 mg), which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014.
Whether you love it, hate it or are just plain confused, the ACA is the law of the land. The thousand-page law covers a lot of ground and figuring out what part of it has to do with you can be a challenge.
› Verified 8 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Michael Weisner, 1201 Grampian Blvd, Williamsport, PA 17701-1900 Ph: () - | Michael Weisner, 900 Plaza Dr, Montoursville, PA 17754-2448 Ph: (570) 368-3037 |
News Archive
Exposure to environments outside a comfortable temperature could help tackle major metabolic diseases, such as diabetes and obesity, and should be reflected in modern building practices, finds a study published today.
Sunshine Biopharma, Inc. a development stage pharmaceutical company focused on the research, development and commercialization of drugs for the treatment of various forms of cancer, today announced that it has executed an agreement with The Research Foundation of the State University of New York (SUNY), acting for and on behalf of Binghamton University (Binghamton, NY).
Alkermes plc today announced positive topline results from a randomized, double-blind, placebo-controlled phase 3 clinical trial of aripiprazole lauroxil in patients with schizophrenia. Patients treated once monthly with either 441 mg or 882 mg of aripiprazole lauroxil demonstrated statistically significant reductions from baseline in Positive and Negative Syndrome Scale (PANSS) total scores at week 12, compared to placebo (p<0.001 aripiprazole lauroxil 441 mg, p<0.001 aripiprazole lauroxil 882 mg), which was the prespecified primary endpoint in the study. Based on the positive results from this phase 3 study, Alkermes plans to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the third quarter of 2014.
Whether you love it, hate it or are just plain confused, the ACA is the law of the land. The thousand-page law covers a lot of ground and figuring out what part of it has to do with you can be a challenge.
› Verified 8 days ago
Dr. Jill A Sharer, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 780 Broad St Ste 4, Montoursville, PA 17754 Phone: 570-368-2870 | |
Timothy Hogan, DO Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 780 Broad St, Montoursville, PA 17754 Phone: 570-368-2870 | |
Namita Gupta, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 780 Broad St, Montoursville, PA 17754 Phone: 570-368-2870 | |
Collier Bussey Nix, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1500 Broad St, Montoursville, PA 17754 Phone: 570-368-2801 Fax: 570-368-0609 | |
Elizabeth Klucka, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 900 Plaza Dr, Montoursville, PA 17754 Phone: 570-601-8574 | |
Dr. Edwin Roman, MD Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1009 Broad St, Suite 1, Montoursville, PA 17754 Phone: 570-368-8389 Fax: 570-368-8391 |